{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020669,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.03.013","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:13:48Z","timestamp":1743905628000},"page":"730-738.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ranking the Importance of Prognostic Factors for Relapsed\/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3134-5136","authenticated-orcid":false,"given":"Beatrice","family":"Suero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Craigie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Spin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3998-736X","authenticated-orcid":false,"given":"Leena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abril Oliva","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-6364","authenticated-orcid":false,"given":"Christian","family":"Hampp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.clml.2025.03.013_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12919-023-00285-8","article-title":"Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion","volume":"18","author":"Fernainy","year":"2024","journal-title":"BMC Proc"},{"issue":"2","key":"10.1016\/j.clml.2025.03.013_bib0002","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002\u20132021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.013_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/spcare-2024-004984","article-title":"Single-arm clinical trials: design, ethics, principles","volume":"15","author":"Wang","year":"2024","journal-title":"BMJ Support Palliat Care"},{"issue":"19","key":"10.1016\/j.clml.2025.03.013_bib0004","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1182\/bloodadvances.2022009167","article-title":"Enriching single-arm clinical trials with external controls: possibilities and pitfalls","volume":"7","author":"Lambert","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2025.03.013_bib0005","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1158\/1078-0432.CCR-19-0820","article-title":"Design and evaluation of an external control arm using prior clinical trials and real-world data","volume":"25","author":"Ventz","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2025.03.013_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.clml.2025.03.013_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"Schneeweiss","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2025.03.013_bib0008","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to \u00a735a Social Code Book V (SGB V). 2020."},{"key":"10.1016\/j.clml.2025.03.013_bib0009","series-title":"NICE DSU Technical Support Document 17: the Use of Observational Data to Inform Estimates of Treatment Effectiveness in Technology Appraisal: Methods for Comparative Individual Patient Data","year":"2015"},{"issue":"1","key":"10.1016\/j.clml.2025.03.013_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.03.013_bib0011","article-title":"Multiple myeloma","volume":"20","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.clml.2025.03.013_bib0012","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.03.013_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.03.013_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2025.03.013_bib0015","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.03.013_bib0016","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2021-144387","article-title":"Efficacy of treatments for patients with triple-class refractory (TCR) multiple myeloma (MM): benchmark for new agents utilizing real-world data (RWD)","volume":"138","author":"Costa","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.03.013_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and outcomes of patients with double-class refractory or triple-class refractory multiple myeloma: a retrospective US electronic health record database study","volume":"64","author":"Wang","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"10.1016\/j.clml.2025.03.013_bib0018","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","article-title":"Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term tollow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma","volume":"23","author":"Mateos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2025.03.013_bib0019","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1080\/03007995.2022.2100651","article-title":"Meta-analysis of ciltacabtagene autoleucel versus physician\u2019s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"38","author":"Costa","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0020","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clml.2025.03.013_bib0021","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0022","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2023.41.16_suppl.8032","volume":"41","author":"Delforge","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.03.013_bib0023","series-title":"Phase 1 study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: results from at least 1-year follow-up in all patients","first-page":"2024","author":"Frigault","year":"2024"},{"key":"10.1016\/j.clml.2025.03.013_bib0024","series-title":"Phase 2 study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma","first-page":"2024","author":"Chen","year":"2024"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0025","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0026","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0027","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0028","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.03.013_bib0029","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2023.41.16_suppl.8039","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Mohty","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.03.013_bib0030","article-title":"S197: LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"HemaSphere"},{"issue":"7_Supplement","key":"10.1016\/j.clml.2025.03.013_bib0031","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2024-CT001","article-title":"Abstract CT001: linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups","volume":"84","author":"Jagannath","year":"2024","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.clml.2025.03.013_bib0032","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.03.013_bib0033","series-title":"Cevostamab in Patients With RRMM Who Are Triple-class Refractory and Have Received a Prior BCMA-targeted ADC or CAR T-cell: Initial Results from the Phase I\/II CAMMA 2 Study","author":"Kumar","year":"2024"},{"issue":"9","key":"10.1016\/j.clml.2025.03.013_bib0034","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2025.03.013_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.03.013_bib0036","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","author":"Costa","year":"2024","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.013_bib0037","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0186","article-title":"Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma","volume":"12","author":"Krishnan","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"2","key":"10.1016\/j.clml.2025.03.013_bib0038","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative effectiveness of teclistamab versus real-world physician's choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.clml.2025.03.013_bib0039","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2025.03.013_bib0040","unstructured":"Higgins JPT TJ, Chandler J., Cumpston M., Li T., Page M.J., Welch V.A. (editors). Cochrane handbook for systematic reviews of interventions version 6.2. Accessed January 17, 2025. https:\/\/training.cochrane.org\/handbook"},{"key":"10.1016\/j.clml.2025.03.013_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.clml.2025.03.013_bib0042","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2025.03.013_bib0043","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2025.03.013_bib0044","series-title":"Distiller SR","author":"Partners","year":"2011"},{"key":"10.1016\/j.clml.2025.03.013_bib0045","unstructured":"Cochrane. QUIPS tool.Pdf - Cochrane methods. Accessed September 15, 2021. https:\/\/methods.cochrane.org\/sites\/methods.cochrane.org.prognosis\/files\/public\/uploads\/QUIPS%20tool.pdf."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:07:38Z","timestamp":1758604058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001053"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranking the Importance of Prognostic Factors for Relapsed\/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}